GlassScriptPhysician profile
Eric Kevin Graham
NPI 1457966913
$16,793.69
in general payments reported to CMS, 2019-2025
37 companies · $4,261 in 2025
The $4,261 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,650 · 2022: $3,160 · 2023: $3,339 · 2024: $4,384 · 2025: $4,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,983.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,596.91 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $1,527.00 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,504.54 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,244.20 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,233.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,096.54 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $988.41 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $964.72 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $864.30 | 2021-2025 | Abilify Asimtufii, Rexulti, Brintellix |
| Tris Pharma INC | $680.21 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| E.R. Squibb & Sons, L.L.C. | $574.02 | 2024-2025 | Cobenfy |
| Corium, LLC | $424.74 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $404.61 | 2021-2023 | Belsomra, Verquvo |
| Vanda Pharmaceuticals INC. | $380.15 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $341.88 | 2022-2025 | Auvelity |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $318.61 | 2021-2025 | Trintellix |
| Noven Therapeutics, LLC | $315.95 | 2023-2025 | Secuado, Xelstrym |
| Validus Pharmaceuticals LLC | $306.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $290.66 | 2021-2022 | |
| Neuronetics, INC. | $273.44 | 2022 | |
| Bausch Health US, LLC | $233.45 | 2021-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $177.65 | 2021-2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $151.15 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $141.54 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $122.84 | 2023-2024 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $107.03 | 2022 | |
| Livanova USA, INC. | $105.48 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Pharmaceuticals, INC. | $96.19 | 2023 | Xelstrym |
| Indivior INC. | $81.30 | 2024 | Perseris |
| Jazz Pharmaceuticals INC. | $70.77 | 2021-2022 | |
| Orexo US, INC. | $61.31 | 2021-2024 | Zubsolv |
| Novo Nordisk INC | $25.00 | 2023 | |
| Eisai INC. | $21.96 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.52 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $17.27 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.02 | 2025 | |
| Owp Pharmaceuticals, INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.